Placebo or no medication Depends on DOA or rate of elimination of trial drugs Issue: sufficient to eliminate carry-over effect During this period- trial data and clinical measures are collected to assess the impact of previous tx Considered as baseline data for subsequent tx Efficient in regards to no. of patients required to collect a data